A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

NCT00000916 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

399

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Indinavir sulfate
DRUG: Lamivudine/Zidovudine
DRUG: Hydroxyurea
DRUG: Lamivudine
DRUG: Stavudine
DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)